GlassScriptPhysician profile
Robert L Gillespie
NPI 1740290873
$79,648.47
in general payments reported to CMS, 2019-2025
15 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,437 · 2021: $1,683 · 2022: $47.42 · 2023: $31K · 2024: $12K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $55K · Travel and Lodging: $4,085 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,850 · Food and Beverage: $1,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $55,062.50 |
| Travel and Lodging | $4,084.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,850.00 |
| Food and Beverage | $1,915.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $59,177.49 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $10,428.21 | 2019-2023 | Watchman |
| Astrazeneca Pharmaceuticals LP | $4,821.60 | 2019-2021 | |
| Irhythm Technologies, INC. | $3,762.50 | 2023 | Zio Xt Patch |
| Abbott Laboratories | $339.29 | 2019-2025 | Aveir, Amplatzer, Gallant |
| Alnylam Pharmaceuticals INC. | $258.54 | 2025 | Amvuttra |
| Amgen INC. | $196.17 | 2019 | |
| Cleerly, INC. | $183.62 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Cvrx, INC. | $128.11 | 2023 | Barostim Neo System |
| Pfizer INC. | $120.27 | 2020 | |
| Merck Sharp & Dohme LLC | $74.30 | 2024 | Verquvo |
| Heartflow, INC. | $49.36 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.71 | 2021-2022 | |
| Akcea Therapeutics, INC. | $36.04 | 2020 | |
| Cathworks, INC. | $24.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.